secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001658247-25-000008
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics gets FDA approval for PALSONIFY (paltusotine) as first oral acromegaly treatment
--------------------------------------------------------------------------------

- FDA approved PALSONIFY (paltusotine) for adults with acromegaly with inadequate response to surgery or not surgical candidates.
- First once-daily oral SST2 agonist; approval based on Phase 3 PATHFNDR-1/2 trials showing rapid, durable biochemical control and reduced symptom burden.
- Product expected available in U.S. early October; CrinetiCARE support program launched for patients.
- MAA under review in EU (CHMP opinion H1 2026); also evaluating paltusotine in Phase 3 CAREFNDR trial for carcinoid syndrome.
- Investor conference call on Sept 25, 2025 at 6:00 pm ET to discuss FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000008/0001658247-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000008/crnx-20250925.htm
  HTML page:      https://secwatch.observer/filing/0001658247-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer